With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
You can learn about ALSF's grant review process here.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Investigating phase separated condensates in FPD to MDS/AML progression||Broad Institute / Zuzana Tothova, MD/PhD||RUNX1 Early Career Investigator Grants||2019||Massachusetts|
|Characterizing Inflammatory Phenotypes Associated with RUNX1 Deficiency||Dana-Farber Cancer Institute / Waihay Wong, MD/PhD||RUNX1 Early Career Investigator Grants||2021||Massachusetts|
|Delivering on the Promise of Germline Genetic Testing for RUNX1 Variants||University of Washington, Seattle / Abbye McEwen||RUNX1 Early Career Investigator Grants||2022||Washington|
|Assessing Clonal Fitness and Mechanisms of Clonal Evolution in FPD-MN||Memorial Sloan-Kettering Cancer Center / Wenbin Xiao, MD/PhD||RUNX1 Early Career Investigator Grants||2020||New York|
|Targeting Spinal Ependymoma and Other Gliomas Using Novel Genetically Defined Models||The Johns Hopkins University School of Medicine / Charles Eberhart, MD, PhD||Catalyst Grants||2019||Maryland|
|GD2-directed CAR T cell therapy for H3K27M+ spinal cord diffuse midline glioma||Board of Trustees of the Leland Stanford Junior University / Michelle Monje||Catalyst Grants||2021||California|
|Cell Line and Xenograft Repository||Texas Tech University Health Sciences Center / Patrick Reynolds, MD/PhD||Catalyst Grants||2014||Texas|
|Characterization of Pre-Leukemia Associated with Familial RUNX1 Mutations||Stanford University / Ravi Majeti, MD/PhD||Familial RUNX1 Research Grants||2016||California|
|Identifying Therapeutic Targets to Prevent Progression of Familial RUNX1 Disorder to AML Using Novel iPSC Models||Icahn School of Medicine at Mount Sinai / Eirini Papapetrou, MD/PhD||Familial RUNX1 Research Grants||2016||New York|
|Pharmacologic Enhancement of Residual Wild Type RUNX1 Protein Activity in FPD/AML||Boston Children's Hospital / Alan Cantor, MD, PhD||Familial RUNX1 Research Grants||2016||Massachusetts|